Study identifier:D1443L00009
ClinicalTrials.gov identifier:NCT00486798
EudraCT identifier:2006-006426-26
CTIS identifier:N/A
-
Psychotic Disorders
Phase 3
No
Quetiapine
All
-
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Apr 2025 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
Location
Location
Goteborg, Sweden
Location
Danderyd, Sweden
Location
Falkoping, Sweden
Location
Karlskrona, Sweden
Location
Malmo, Sweden
Location
Ojebyn, Sweden
Location
Pitea, Sweden
Location
Simrishamn, Sweden
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.